Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate a
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... , Sept. 30, 2014  KemPharm, Inc., a ... and development of proprietary new molecular entity (NME) ... and Trademark Office (USPTO) issued U.S. Patent No. ... "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic ... and Use Thereof." The patent, which ...
(Date:9/30/2014)... 30, 2014 The custom stainless steel ... Product Show 2014. The Boston Area Chapter of ISPE ... annual, day-long event for Wed., Oct. 1 at Gillette ... be the largest in ISPE Boston’s long history, with ... 3,000 attendees expected. , HOLLOWAY AMERICA President David ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 UFP ... and specialty packaging has recently introduced a custom ... Suspension Pack . The new insulated shipper solves ... chain distribution process. UFP Technologies’ BioShell is a ... bags during storage, handling and shipping. The insulated ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... Corp ., a Madison biotechnology company, has raised $1 million ... the total raised to $3 million in the past two ... verify the efficacy of two products: adhesives that bind tissues ... and medical device coatings that block bacterial adhesion to the ...
... - Sir Ken Robinson has many ... his point about creativity than the story of a little ... a senior advisor to the J. Paul Getty Trust ... creativity and innovation, told the story during a keynote address ...
... 1995, I gave a luncheon speech to the Chicago Bar ... st Century." At that time, many who attended ... that much faith in it. My argument was that the ... maxed out. Municipalities would have to become more creative to ...
Cached Biology Technology:Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 2Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 3Creativity, innovation extend to municipalities 2Creativity, innovation extend to municipalities 3Creativity, innovation extend to municipalities 4
(Date:9/30/2014)... news release is available in German . ... are among the most expensive foods in the world. Because ... find them. But the distinctive smell of truffles is not ... French scientists under the direction of the Goethe University Frankfurt ... produced by soil bacteria which are trapped inside truffle fruiting ...
(Date:9/30/2014)... goes wrong with your muscles because of age, disease or ... is. That,s where a new research report published in the ... comes in. In the report, a team of scientists ... help scientists "see" which genes are active in an organ ... activity and that men have approximately 400 more active genes ...
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Scientists identify which genes are active in muscles of men and women 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... United States are changing and will face reduced growth ... this century, according to a study conducted by a ... of California, Santa Barbara; U.S. Geological Survey; and University ... Proceedings of the National Academy of Sciences ...
... It,s colds and flu season, and as any parent knows, ... New research using human-networking theory may give a clearer picture ... cold, influenza, whooping cough and SARS can spread through a ... With the help of 788 volunteers at a high ...
... ever, scientists have found a difference in the way males and ... that sexes likely use that difference to select their mates. ... team of researchers who found that male and female cichlid fishes ... as well. "It is difficult to say what colour ...
Cached Biology News:Drought and rising temperatures weaken southwest forests 2Human networking theory gives picture of infectious disease spread 2Human networking theory gives picture of infectious disease spread 3When it comes to selecting a mate, the eyes have it: Queen's University study 2
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
POU domain, class 2, transcription factor 2,...
Biology Products: